Results of a clinical trial for Point Biopharma’s lead compound fell short of analysts’ expectations, and that development is likely to pressure its investors to decide whether to agree to sell the company to Eli Lilly and Co. for $1.4 billion.
VillageMD, a subsidiary of Chicago-based pharmacy giant Walgreens Boots Alliance, is closing more than 60 primary care clinics in five markets, including nine practices in northern Indiana and four in central Indiana.
The new drug, called Zepbound, carries a hefty price of $1,059.87 per month, and insurers and health care plans are balking, questioning its affordability. Many employers and government health programs exclude obesity treatments from their coverage.
The city wants to build a “housing hub” that will include the city’s first low-barrier homeless shelter on 11 parcels at the intersection of Shelby and East Georgia streets.
The company, Carmot Therapeutics, has numerous drugs under development. Its lead asset is a once-a-week injection that is in mid-stage development for the treatment of obesity.
In March, Eskenazi Health launched a fundraising campaign to help it move the needle on health disparities. As of last month, its foundation had raised $57 million.
Speaking at Monday’s Economic Club of Indiana, Corteva CEO Chuck Magro said last year’s decision was anything but hasty or haphazard.
The two companies have been battling for years over patents for migraine headache drugs—Emgality for Lilly and Anjovy for Teva. Both drugs are once-monthly injections and were approved 13 days apart in September 2018.
The utility’s initial proposal provoked widespread objections, including from more than 40 customers who attended two field hearings.
The live-work-play campus has been picked to join a new national network designed to connect researchers, entrepreneurs and investors to accelerate the development of health care products and services and speed up health care innovations.
The Indianapolis-based philanthropy giant says the grants are intended to help immigrants acclimate to life in central Indiana and make progress toward self-sufficiency.
The Bloomington plant, with about 1,000 employees, is the fifth-largest employer in Monroe County, according to the Greater Bloomington Chamber of Commerce, and is poised for more growth.
Some warn that the spiraling number of deals could lead to large physician groups having an unfairly high market share, which could lead to price increases and cost-cutting.
The extension comes amid pushback from several investors, including Point’s largest institutional stock holder.
The announcement represents the company’s latest move to meet the soaring demand for its medicines for diabetes and weight loss.
The business makes a hand-sanitizing device called Iggy that kills pathogens with ozone-infused water instead of soap or other chemicals.
Point has a pipeline of clinical and preclinical-stage compounds in development for the treatment of cancer using radiopharmaceutical isotopes that hold the promise of delivering targeted treatments to cancer patients.
Consumer advocates and other across the country and in central Indiana are saying big executive-compensation packages are ripe for review.
Republic Services called the development the “nation’s first integrated plastics recycling facility,” designed to address increasing demand from consumers and packaging manufacturers for recycled plastic.
The Indianapolis-based drug company is ramping up manufacturing capacity to avoid possible shortages and to meet potentially huge demand in a nation where more than 40% of adults are classified as obese.
